References
- Trenkwalder C, Stiasny-Kolster K, Kupsch A, et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord. 2006;21:1404-1410.
- Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006;67:1034-1039.
- Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
- Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
- Chaudhuri KR, Forbes A, Grosset D, et al. Diagnosing restless legs syndrome (RLS) in primary care. Curr Med Res Opin. 2004;20:1785-1795.
- Desautels A, Turecki G, Montplaisir J, et al. Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol. 2005;62:591-596.
- Avecillas JF, Golish JA, Giannini C, Yataco JC. Restless legs syndrome: keys to recognition and treatment. Cleve Clin J Med. 2005;72:769-787.
- National Heart, Lung, and Blood Institute Working Group on Restless Legs Syndrome. Restless legs syndrome: detection and management in primary care. Am Fam Physician. 2000;62:108-114.
- Mirapex [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2007.
- Hening W, Walters AS, Allen RP, et al. Impact, diagnosis, and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5:237-246.
- The International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121-132.
- Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101-119.
- Guy W. ECDEU Assessment Manual for Psychopharmacology. rev ed. Rockville, Md: US National Institutes of Health, Psychopharmacology Research Branch; 1976:218-222. ADM publication 76-338. Reprinted by: US Dept of Health and Human Services; 1991. ADM publication 91-338.
- Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc. 2004;79:916-922.
- Centers for Medicare & Medicaid Services. Decision memo for serum iron studies (addition of restless leg syndrome as a covered indication) (CAG-00263R). http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=178.
- Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
- Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
Learn about RLS
Learn about MIRAPEX
Learn more about clinical evaluation when making a diagnosis of Restless Legs Syndrome (RLS)
Learn more about clinical evaluation [link to: 9.1] when making a diagnosis of Restless Legs Syndrome (RLS)
Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for RLS, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (16% vs. 5%), headache (16% vs. 15%), fatigue (9% vs. 7%) and somnolence (6% vs. 3%).
Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.
This information is intended for U.S. residents only. Products discussed herein may have different labeling in different countries.
Please see full Prescribing Information, including patient information.
